Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Efficacy of Liposomal Bupivacaine in the Management of Post-operative Pain Following Septorhinoplasty
NCT05964868Phase 3Enrolling by invitation
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of liposomal bupivacaine in postoperative pain (3 arms). Primary endpoint: Milligram Morphine Equivalents at 6 months. Started Feb 2024; status: enrolling by invitation.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05964868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05964868.